Chunghwa Telecom Co. Ltd. ADS (CHT) Financials Nov 18,
Chunghwa Telecom Co. Ltd. ADS (CHT) Financials Nov 18, 2014, 11:39 a.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Chunghwa Telecom Co. Ltd. ADS
Fiscal year is January-December. All values TWD millions. 2009 2010 2011 2012 2013 5-year trend
Sales/Revenue 198.36B 202.43B 217.49B 221.42B 227.98B
Cost of Goods Sold (COGS) incl. D&A 114.91B 117.32B 133.51B 143.72B 149.68B
COGS excluding D&A 78.59B 83.26B 101.21B 111.56B 117.49B
Depreciation & Amortization Expense 36.32B 34.06B 32.31B 32.16B 32.19B
Depreciation 35.13B 32.75B 30.91B 31.04B 30.95B
Amortization of Intangibles 1.19B 1.31B 1.4B 1.12B 1.24B
Gross Income 83.45B 85.11B 83.98B 77.7B 78.3B
2009 2010 2011 2012 2013 5-year trend
SG&A Expense 27.05B 27.74B 28.9B 27.76B 30.68B
Research & Development 3.17B 3.25B 3.53B 3.7B 3.72B
Other SG&A 23.88B 24.49B 25.37B 24.06B 26.96B
Other Operating Expense 0 0 0 0 0
Unusual Expense 11.31M 155.34M 185.47M 1.77B 93.58M
EBIT after Unusual Expense (11.31M) (155.34M) (185.47M) (1.77B) (93.58M)
Non Operating Income/Expense 415.06M (42.6M) 784.18M 502.44M 382.67M
Non-Operating Interest Income 478.71M 475.46M 681.86M 741.94M 562.81M
Equity in Affiliates (Pretax) (23.22M) - - - -
Interest Expense 15.22M 107.25M 30.71M 19.93M 32.94M
Gross Interest Expense 15.43M 107.26M 30.79M 19.93M 32.94M
Interest Capitalized 207,000 11,000 78,000 - -
Pretax Income 57.24B 57.54B 56.33B 49.39B 48.44B
Income Tax 12.74B 9.13B 8.6B 8.01B 8.27B
Income Tax - Current Domestic 11.64B 9.1B 8.52B 8.02B 8.37B
Income Tax - Current Foreign - - 27.37M 0 0
Income Tax - Deferred Domestic 1.1B 26.57M 57.09M (3.97M) (100.76M)
Income Tax - Deferred Foreign - - - 0 0
Income Tax Credits 0 0 0 0 0
Equity in Affiliates - 150.68M 364M 533.36M 674.98M
Other After Tax Income (Expense) 0 0 0 0 0
Consolidated Net Income 44.5B 48.56B 48.1B 41.92B 40.84B
Minority Interest Expense 737.73M 949.4M 1.03B 1.14B 1.12B
Net Income 43.76B 47.61B 47.07B 40.78B 39.72B
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg 0 0 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries 43.76B 47.61B 47.07B 40.78B 39.72B
Preferred Dividends 0 0 0 0 0
Net Income Available to Common 43.76B 47.61B 47.07B 40.78B 39.72B
EPS (Basic) 6.20 6.14 6.04 5.26 5.12
Basic Shares Outstanding 7.05B 7.76B 7.79B 7.76B 7.76B
EPS (Diluted) 6.19 6.11 6.03 5.24 5.11
Diluted Shares Outstanding 7.07B 7.78B 7.81B 7.78B 7.77B
EBITDA 92.71B 91.43B 87.39B 82.1B 79.81B
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Femoral access may be the unglamorous part of a valve procedure, but it is where an otherwise tidy case can turn ugly in a hurry. That makes Ladera Medical's full FASTEN data worth a careful look. The company reported results in 55 patients undergoing transfemoral TAVR/TAVI, and the numbers presented at London Valves 2026 suggest its large-bore closure system may address...
Continue Reading
A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...
Continue Reading
Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...
Continue Reading
Three hundred-plus pipelines is a lot of messy plumbing to tame, and NatGasHub has apparently found a lucrative way to do it. The Houston software company landed at No. 182 on Deloitte’s 2026 Technology Fast 500 after reporting 391% revenue growth from 2022 through 2025. That is a serious number, even in a ranking built to showcase companies sprinting uphill. More...
Continue Reading
A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...
Continue Reading
Influence is getting harder to measure, and easier to squander, which is why the message from Ajman deserves more than a polite nod. At the 2026 Ajman Media Forum, THE SIGNAL, Foreign Affairs Undersecretary Omar Obaid Alhesan Alshamsi made the UAE’s position plain: diplomacy and media are no longer separate lanes. Both operate on words, context, trust and the difficult...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading